Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage

Authors: Anna Ambrosini, Daniela Calabrese, Francesco Maria Avato, Felice Catania, Guido Cavaletti, Maria Carmela Pera, Antonio Toscano, Giuseppe Vita, Lucia Monaco, Davide Pareyson

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

The worldwide landscape of patient registries in the neuromuscular disease (NMD) field has significantly changed in the last 10 years, with the international TREAT-NMD network acting as strong driver. At the same time, the European Medicines Agency and the large federations of rare disease patient organizations (POs), such as EURORDIS, contributed to a great cultural change, by promoting a paradigm shift from product-registries to patient-centred registries. In Italy, several NMD POs and Fondazione Telethon undertook the development of a TREAT-NMD linked patient registry in 2009, with the referring clinical network providing input and support to this initiative through the years. This article describes the outcome of this joint effort and shares the experience gained.

Methods

The Italian NMD registry is based on an informatics technology platform, structured according to the most rigorous legal national and European requirements for management of patient sensitive data. A user-friendly web interface allows both direct patients and clinicians’ participation. The platform’s design permits expansion to incorporate new modules and new registries, and is suitable of interoperability with other international efforts.

Results

When the Italian NMD Registry was initiated, an ad hoc legal entity (NMD Registry Association) was devised to manage registries’ data. Currently, several disease-specific databases are hosted on the platform. They collect molecular and clinical details of individuals affected by Duchenne or Becker muscular dystrophy, Charcot-Marie-Tooth disease, transthyretin type-familial amyloidotic polyneuropathy, muscle glycogen storage disorders, spinal and bulbar muscular atrophy, and spinal muscular atrophy. These disease-specific registries are at different stage of development, and the NMD Registry itself has gone through several implementation steps to fulfil different technical and governance needs. The new governance model is based on the agreement between the NMD Registry Association and the professional societies representing the Italian NMD clinical network. Overall, up to now the NMD registry has collected data on more than 2000 individuals living with a NMD condition.

Conclusions

The Italian NMD Registry is a flexible platform that manages several condition-specific databases and is suitable to upgrade. All stakeholders participate in its management, with clear roles and responsibilities. This governance model has been key to its success. In fact, it favored patient empowerment and their direct participation in research, while also engaging the expert clinicians of the Italian network in the collection of accurate clinical data according to the best clinical practices.
Appendix
Available only for authorised users
Literature
1.
go back to reference Emery AEH. Neuromuscular disorders. Clinical and molecular genetics. Chichester: John Wiley & Sons; 1998. Emery AEH. Neuromuscular disorders. Clinical and molecular genetics. Chichester: John Wiley & Sons; 1998.
2.
go back to reference Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381(9869):845–60.CrossRef Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381(9869):845–60.CrossRef
3.
go back to reference Rossor AM, Carr AS, Devine H, Chandrashekar H, Pelayo-Negro AL, Pareyson D, et al. Peripheral neuropathy in complex inherited diseases: an approach to diagnosis. J Neurol Neurosurg Psychiatry. 2017;88(10):846–63.CrossRef Rossor AM, Carr AS, Devine H, Chandrashekar H, Pelayo-Negro AL, Pareyson D, et al. Peripheral neuropathy in complex inherited diseases: an approach to diagnosis. J Neurol Neurosurg Psychiatry. 2017;88(10):846–63.CrossRef
5.
go back to reference Bushby K, Lynn S, Straub T, Network T-N. Collaborating to bring new therapies to the patient-the TREAT-NMD model. Acta Myol. 2009;1:12–5. Bushby K, Lynn S, Straub T, Network T-N. Collaborating to bring new therapies to the patient-the TREAT-NMD model. Acta Myol. 2009;1:12–5.
6.
go back to reference Lochmüller H, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P, et al. ‘IRDiRC recognized Resources’: a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases. Eur J Hum Genet. 2017;25(2):162–5.CrossRef Lochmüller H, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P, et al. ‘IRDiRC recognized Resources’: a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases. Eur J Hum Genet. 2017;25(2):162–5.CrossRef
8.
go back to reference Piscosquito G, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Responsiveness of clinical outcome measures in Charcot-Marie-tooth disease. Eur J Neurol. 2015;22(12):1556–63.CrossRef Piscosquito G, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Responsiveness of clinical outcome measures in Charcot-Marie-tooth disease. Eur J Neurol. 2015;22(12):1556–63.CrossRef
9.
go back to reference Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ. DMD Italian group; trajectory analysis project (cTAP). Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(9):576–83.CrossRef Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ. DMD Italian group; trajectory analysis project (cTAP). Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(9):576–83.CrossRef
10.
go back to reference Messina S, Vita GL, Sframeli M, Mondello S, Mazzone E, D'Amico A, et al. Health-related quality of life and functional changes in DMD: a 12-month longitudinal cohort study. Neuromuscul Disord. 2016;3:189–96.CrossRef Messina S, Vita GL, Sframeli M, Mondello S, Mazzone E, D'Amico A, et al. Health-related quality of life and functional changes in DMD: a 12-month longitudinal cohort study. Neuromuscul Disord. 2016;3:189–96.CrossRef
12.
go back to reference Pareyson D, Fratta P, Pradat PF, Sorarù G, Finsterer J, Vissing J, et al. Towards a European registry and biorepository for patients with spinal and bulbar muscular atrophy. J Mol Neurosci. 2016;58(3):394–400.CrossRef Pareyson D, Fratta P, Pradat PF, Sorarù G, Finsterer J, Vissing J, et al. Towards a European registry and biorepository for patients with spinal and bulbar muscular atrophy. J Mol Neurosci. 2016;58(3):394–400.CrossRef
13.
go back to reference Merlini L, Solari A, Vita G, Bertini E, Minetti C, Mongini T, et al. Role of gabapentin in spinal muscle atrophy: results of a multicenter, randomised Italian study. J Child Neurology. 2003;18:537–41.CrossRef Merlini L, Solari A, Vita G, Bertini E, Minetti C, Mongini T, et al. Role of gabapentin in spinal muscle atrophy: results of a multicenter, randomised Italian study. J Child Neurology. 2003;18:537–41.CrossRef
14.
go back to reference Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Ascorbic acid in Charcot-Marie-tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011;10(4):320–8.CrossRef Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Ascorbic acid in Charcot-Marie-tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011;10(4):320–8.CrossRef
15.
go back to reference Gliklich RE, Dreyer NA. Leavy MA (eds). Registries for evaluating patient outcomes: a User’s guide. Third edition. (prepared by the outcome DEcIDE Centre [outcome sciences, Inc., a quintiles company] under contract no. 290 2005 00351 TO7). AHRQ publication no. 13(14)-EHC111. Rockville: Agency for Healthcare Research and Quality; 2014. Gliklich RE, Dreyer NA. Leavy MA (eds). Registries for evaluating patient outcomes: a User’s guide. Third edition. (prepared by the outcome DEcIDE Centre [outcome sciences, Inc., a quintiles company] under contract no. 290 2005 00351 TO7). AHRQ publication no. 13(14)-EHC111. Rockville: Agency for Healthcare Research and Quality; 2014.
24.
go back to reference Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, et al. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat. 2013;34(11):1449–57.CrossRef Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, et al. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat. 2013;34(11):1449–57.CrossRef
25.
go back to reference Bladen CL, Thompson R, Jackson JM, Garland C, Wegel C, Ambrosini A, et al. Mapping the differences in care for 5000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J Neurol. 2014;261(1):152–63.CrossRef Bladen CL, Thompson R, Jackson JM, Garland C, Wegel C, Ambrosini A, et al. Mapping the differences in care for 5000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J Neurol. 2014;261(1):152–63.CrossRef
29.
go back to reference Sansone VA, Racca F, Ottonello G, Vianello A, Berardinelli A, Crescimanno G, Casiraghi JL on behalf of the Italian SMA Family Association. 1st Italian SMA family association consensus meeting: management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I–III, Rome, Italy, 30–31 January 2015. Neuromuscul Disord 2015;25:979–989. Sansone VA, Racca F, Ottonello G, Vianello A, Berardinelli A, Crescimanno G, Casiraghi JL on behalf of the Italian SMA Family Association. 1st Italian SMA family association consensus meeting: management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I–III, Rome, Italy, 30–31 January 2015. Neuromuscul Disord 2015;25:979–989.
30.
go back to reference Messina S, Pane M, Sansone V, Bruno C, Catteruccia M, Vita G, et al. Expanded access program with Nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience. Neuromuscul Disord. 2017;12:1084–6.CrossRef Messina S, Pane M, Sansone V, Bruno C, Catteruccia M, Vita G, et al. Expanded access program with Nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience. Neuromuscul Disord. 2017;12:1084–6.CrossRef
31.
go back to reference Sansone VA, Pane M, Messina S, Bruno C, D'Amico A, Albamonte E, et al. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of European Journal of Pediatric Neurology regarding the manuscript “Single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1” written by Pechmann and colleagues. Eur J Paediatr Neurol. 2018;S1090–3798(18):30015–1. Sansone VA, Pane M, Messina S, Bruno C, D'Amico A, Albamonte E, et al. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of European Journal of Pediatric Neurology regarding the manuscript “Single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1” written by Pechmann and colleagues. Eur J Paediatr Neurol. 2018;S1090–3798(18):30015–1.
33.
go back to reference Reilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC international workshop: outcome measures and clinical trials in Charcot-Marie-tooth disease (CMT). Neuromuscul Disord. 2010;20(12):839–46.CrossRef Reilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC international workshop: outcome measures and clinical trials in Charcot-Marie-tooth disease (CMT). Neuromuscul Disord. 2010;20(12):839–46.CrossRef
34.
go back to reference Merkel PA, Manion M, Gopal-Srivastava R, Groft S, Jinnah HA, Robertson D, et al. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis. 2016;11(1):66.CrossRef Merkel PA, Manion M, Gopal-Srivastava R, Groft S, Jinnah HA, Robertson D, et al. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis. 2016;11(1):66.CrossRef
35.
go back to reference Murphy SM, Herrmann DN, McDermott MP, Scherer SS, Shy ME, Reilly MM, Pareyson D. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-tooth disease. J Peripher Nerv Syst. 2011;16(3):191–8.CrossRef Murphy SM, Herrmann DN, McDermott MP, Scherer SS, Shy ME, Reilly MM, Pareyson D. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-tooth disease. J Peripher Nerv Syst. 2011;16(3):191–8.CrossRef
36.
go back to reference Burns J, Ouvrier R, Estilow T, Shy R, Laurá M, Pallant JF, et al. Validation of the Charcot-Marie-tooth disease pediatric scale as an outcome measure of disability. Ann Neurol. 2012;71(5):642–52.CrossRef Burns J, Ouvrier R, Estilow T, Shy R, Laurá M, Pallant JF, et al. Validation of the Charcot-Marie-tooth disease pediatric scale as an outcome measure of disability. Ann Neurol. 2012;71(5):642–52.CrossRef
37.
go back to reference Pennuto M, Greensmith L, Pradat PF. Sorarù G; European SBMA consortium. 210th ENMC international workshop: research and clinical management of patients with spinal and bulbar muscular atrophy, 27-29 march, 2015, Naarden, the Netherlands. Neuromuscul Disord. 2015;25(10):802–12.CrossRef Pennuto M, Greensmith L, Pradat PF. Sorarù G; European SBMA consortium. 210th ENMC international workshop: research and clinical management of patients with spinal and bulbar muscular atrophy, 27-29 march, 2015, Naarden, the Netherlands. Neuromuscul Disord. 2015;25(10):802–12.CrossRef
38.
go back to reference Hashizume A, Katsuno M, Suzuki K, Banno H, Suga N, Mano T, et al. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord. 2015;25(7):554–62.CrossRef Hashizume A, Katsuno M, Suzuki K, Banno H, Suga N, Mano T, et al. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord. 2015;25(7):554–62.CrossRef
39.
go back to reference Querin G, DaRe E, Martinelli I, Bello L, Bertolin C, Pareyson D, et al. Validation of the Italian version of the SBMA functional rating scale as outcome measure. Neurol Sci. 2016;37(11):1815–21.CrossRef Querin G, DaRe E, Martinelli I, Bello L, Bertolin C, Pareyson D, et al. Validation of the Italian version of the SBMA functional rating scale as outcome measure. Neurol Sci. 2016;37(11):1815–21.CrossRef
40.
go back to reference Morrow JM, Sinclair CD, Fischmann A, Machado PM, Reilly MM, Yousry TA, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol. 2016;15(1):65–77.CrossRef Morrow JM, Sinclair CD, Fischmann A, Machado PM, Reilly MM, Yousry TA, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol. 2016;15(1):65–77.CrossRef
41.
go back to reference Schoser B, Laforêt P, Kruijshaar ME, Toscano A, van Doorn PA, van der Ploeg AT. European Pompe consortium (EPOC). 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26-28 September 2014. Neuromuscul Disord. 2015;25(8):674–8.CrossRef Schoser B, Laforêt P, Kruijshaar ME, Toscano A, van Doorn PA, van der Ploeg AT. European Pompe consortium (EPOC). 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26-28 September 2014. Neuromuscul Disord. 2015;25(8):674–8.CrossRef
42.
go back to reference Quinlivan R, Andreu AL, Marti R. Workshop Participants. 211th ENMC International Workshop: Development of diagnostic criteria and management strategies for McArdle Disease and related rare glycogenolytic disorders to improve standards of care. 17-19 April 2015, Naarden, The Netherlands. Neuromuscul Disord. 2017;27(12):1143–51.CrossRef Quinlivan R, Andreu AL, Marti R. Workshop Participants. 211th ENMC International Workshop: Development of diagnostic criteria and management strategies for McArdle Disease and related rare glycogenolytic disorders to improve standards of care. 17-19 April 2015, Naarden, The Netherlands. Neuromuscul Disord. 2017;27(12):1143–51.CrossRef
43.
go back to reference Mariani LL, Lozeron P, Théaudin M, Mincheva Z, , Signate A, Ducot B, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015;78(6):901–916.CrossRef Mariani LL, Lozeron P, Théaudin M, Mincheva Z, , Signate A, Ducot B, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015;78(6):901–916.CrossRef
44.
go back to reference Parman Y, Adams D, Obici L, Galán L, Guergueltcheva V, Suhr OB, Coelho T. European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3–S13.CrossRef Parman Y, Adams D, Obici L, Galán L, Guergueltcheva V, Suhr OB, Coelho T. European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3–S13.CrossRef
45.
go back to reference Luigetti M, Conte A, Del Grande A, Bisogni G, Madia F, Lo Monaco M, et al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci. 2013;34(7):1057–63.CrossRef Luigetti M, Conte A, Del Grande A, Bisogni G, Madia F, Lo Monaco M, et al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci. 2013;34(7):1057–63.CrossRef
46.
go back to reference Mazzeo A, Russo M, Di Bella G, Minutoli F, Stancanelli C, Gentile L, et al. Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area. J Neuromuscular Diseases. 2015;(Suppl 2):S39–48.CrossRef Mazzeo A, Russo M, Di Bella G, Minutoli F, Stancanelli C, Gentile L, et al. Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area. J Neuromuscular Diseases. 2015;(Suppl 2):S39–48.CrossRef
47.
go back to reference Taruscio D, Mollo E, Gainotti S, de la Paz Posada M, Bianchi F, Vittozzi L. The EPIRARE proposal of a set of indicators and common data elements for the European platform for rare disease registration. Arch Public Health. 2014;72(1):35.CrossRef Taruscio D, Mollo E, Gainotti S, de la Paz Posada M, Bianchi F, Vittozzi L. The EPIRARE proposal of a set of indicators and common data elements for the European platform for rare disease registration. Arch Public Health. 2014;72(1):35.CrossRef
48.
go back to reference Gainotti S, Torreri P, Wang CM, Reihs R, Mueller H, Heslop E, et al. The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. Eur J Hum Genet. 2018;26(5):631–43.CrossRef Gainotti S, Torreri P, Wang CM, Reihs R, Mueller H, Heslop E, et al. The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. Eur J Hum Genet. 2018;26(5):631–43.CrossRef
50.
go back to reference Wang RT. Nelson SF what can Duchenne connect teach us about treating Duchenne muscular dystrophy? Curr Opin Neurol. 2015;28(5):535–41.CrossRef Wang RT. Nelson SF what can Duchenne connect teach us about treating Duchenne muscular dystrophy? Curr Opin Neurol. 2015;28(5):535–41.CrossRef
51.
go back to reference Rodrigues MJ, O'Grady GL, Hammond-Tooke G, Kidd A, Love DO, Baker RK, Roxburgh RH. The New Zealand neuromuscular disease patient registry; five years and a thousand patients. J Neuromuscul Dis. 2017;4(3):183–8.CrossRef Rodrigues MJ, O'Grady GL, Hammond-Tooke G, Kidd A, Love DO, Baker RK, Roxburgh RH. The New Zealand neuromuscular disease patient registry; five years and a thousand patients. J Neuromuscul Dis. 2017;4(3):183–8.CrossRef
53.
go back to reference Kaye J, Terry SF, Juengst E, Coy S, Harris JR, Chalmers D, et al. Including all voices in international data sharing. Human Genomics. 2018;12(1):13.CrossRef Kaye J, Terry SF, Juengst E, Coy S, Harris JR, Chalmers D, et al. Including all voices in international data sharing. Human Genomics. 2018;12(1):13.CrossRef
54.
go back to reference Thompson R, Johnston L, Taruscio D, Monaco L, Béroud C, Gut IG, et al. RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J Gen Intern Med. 2014;29(Suppl 3):S780–7.CrossRef Thompson R, Johnston L, Taruscio D, Monaco L, Béroud C, Gut IG, et al. RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J Gen Intern Med. 2014;29(Suppl 3):S780–7.CrossRef
56.
go back to reference Lochmüller H, Badowska DM, Thompson R, Knoers NV, Aartsma-Rus A, Gut I, et al. RD-connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Eur J Hum Genet. 2018;26(6):778–85.CrossRef Lochmüller H, Badowska DM, Thompson R, Knoers NV, Aartsma-Rus A, Gut I, et al. RD-connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Eur J Hum Genet. 2018;26(6):778–85.CrossRef
57.
go back to reference Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR guiding principles for scientific data management and stewardship. Nature Sci Data. 2016;3:160018.CrossRef Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR guiding principles for scientific data management and stewardship. Nature Sci Data. 2016;3:160018.CrossRef
58.
go back to reference Thompson R, Robertson A, Lochmüller H. Natural history, trial readiness and gene discovery: advances in patient registries for neuromuscular diseases. In: de la Paz Posada M, Taruscio D, Groft S, editors. Rare diseases epidemiology: update and overview. Advances in experimental medicine and biology, vol. 1031. Cham: Springer; 2017. p. 97–124.CrossRef Thompson R, Robertson A, Lochmüller H. Natural history, trial readiness and gene discovery: advances in patient registries for neuromuscular diseases. In: de la Paz Posada M, Taruscio D, Groft S, editors. Rare diseases epidemiology: update and overview. Advances in experimental medicine and biology, vol. 1031. Cham: Springer; 2017. p. 97–124.CrossRef
59.
go back to reference Köhler S, Vasilevsky NA, Engelstad M, Foster E, McMurry J, Aymé S, et al. The human phenotype ontology in 2017. Nucleic Acids Res. 2017;45(D1):D865–76.CrossRef Köhler S, Vasilevsky NA, Engelstad M, Foster E, McMurry J, Aymé S, et al. The human phenotype ontology in 2017. Nucleic Acids Res. 2017;45(D1):D865–76.CrossRef
60.
go back to reference Neurological Registry Best Practice Guidelines. Canadian J Neurol Sciences. 2013;40(Issue S2):S1–S80. Neurological Registry Best Practice Guidelines. Canadian J Neurol Sciences. 2013;40(Issue S2):S1–S80.
61.
go back to reference Pogoryelova O, Cammish P, Mansbach H, Argov Z, Nishino I, Skrinar A, et al. Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: first report from the GNE myopathy disease monitoring program, registry portion. Neuromuscul Disord. 2018;28(2):158–68.CrossRef Pogoryelova O, Cammish P, Mansbach H, Argov Z, Nishino I, Skrinar A, et al. Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: first report from the GNE myopathy disease monitoring program, registry portion. Neuromuscul Disord. 2018;28(2):158–68.CrossRef
62.
go back to reference Muenzer J, Jones SA, Tylki-Szymańska A, Harmatz P, Nancy J, Mendelsohn NJ, et al. Ten years of the hunter outcome survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet Journal of Rare Diseases. 2017;12:82.CrossRef Muenzer J, Jones SA, Tylki-Szymańska A, Harmatz P, Nancy J, Mendelsohn NJ, et al. Ten years of the hunter outcome survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet Journal of Rare Diseases. 2017;12:82.CrossRef
66.
go back to reference Lochmüller H, Evans D, Farwell W, Finkel R, Goemans N. Mencia de Lemus M, et al. position statement: sharing of clinical research data in spinal muscular atrophy to accelerate research and improve outcomes for patients. J Neuromusc Dis. 2018;5:131–3.CrossRef Lochmüller H, Evans D, Farwell W, Finkel R, Goemans N. Mencia de Lemus M, et al. position statement: sharing of clinical research data in spinal muscular atrophy to accelerate research and improve outcomes for patients. J Neuromusc Dis. 2018;5:131–3.CrossRef
68.
go back to reference Weinreb NJ, Kaplan P. The history and accomplishments of the ICGG Gaucher registry. Am J Hematology. 2015;90(Suppl 1):S2–5.CrossRef Weinreb NJ, Kaplan P. The history and accomplishments of the ICGG Gaucher registry. Am J Hematology. 2015;90(Suppl 1):S2–5.CrossRef
69.
go back to reference Li G, Sajobi TT, Menon BK, Lawrence Korngut L, Lowerison C, et al. Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research? J Clinical Epidemiology. 2016;80:16–24.CrossRef Li G, Sajobi TT, Menon BK, Lawrence Korngut L, Lowerison C, et al. Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research? J Clinical Epidemiology. 2016;80:16–24.CrossRef
70.
go back to reference de Groot S, van der Linden N, Franken MG, Blommestein HM, Leeneman B, van Rooijen E, et al. Balancing the optimal and the feasible: a practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value Health. 2017;20(4):627–36.CrossRef de Groot S, van der Linden N, Franken MG, Blommestein HM, Leeneman B, van Rooijen E, et al. Balancing the optimal and the feasible: a practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value Health. 2017;20(4):627–36.CrossRef
71.
go back to reference Koeks Z, Bladen CL, Salgado D, van Zwet E, Pogoryelova O, McMacken G, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4(4):293–306.CrossRef Koeks Z, Bladen CL, Salgado D, van Zwet E, Pogoryelova O, McMacken G, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4(4):293–306.CrossRef
72.
go back to reference Viviani L, Zolin A, Mehta A, Olesen HV. The European cystic fibrosis society patient registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis. 2014;9:81.CrossRef Viviani L, Zolin A, Mehta A, Olesen HV. The European cystic fibrosis society patient registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis. 2014;9:81.CrossRef
74.
go back to reference Woodward L, Johnson S, Walle JV, Beck J, Gasteyger C, Licht C, et al. An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the global aHUS registry. Orphanet J Rare Dis. 2016;11(1):154.CrossRef Woodward L, Johnson S, Walle JV, Beck J, Gasteyger C, Licht C, et al. An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the global aHUS registry. Orphanet J Rare Dis. 2016;11(1):154.CrossRef
75.
go back to reference Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. Pharmacoepidemiol Drug Saf 2017;26(12):1442–1450.CrossRef Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. Pharmacoepidemiol Drug Saf 2017;26(12):1442–1450.CrossRef
Metadata
Title
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage
Authors
Anna Ambrosini
Daniela Calabrese
Francesco Maria Avato
Felice Catania
Guido Cavaletti
Maria Carmela Pera
Antonio Toscano
Giuseppe Vita
Lucia Monaco
Davide Pareyson
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0918-z

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue